IP Library Granted Patent US 10,619,134
Granted Patent B2
US 10,619,134 · App. 15/499,124 · Granted Apr 14, 2020

Use of BMP4 for thymic regeneration

Inventors: Jarrod Dudakov (Seattle, WA); Marcel Van Den Brink (New York, NY); Tobias Wertheimer (Freiburg, DE)
Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTER
C12N5/0617A61K38/1875C07K14/005C07K14/51C12N5/10C12N2501/155C12N2710/10322
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,619,134
App. No.
15/499,124
Granted
Apr 14, 2020
Kind
B2
Abstract

The present disclosure describes methods to promote thymic regeneration following injury or damage to the thymus by administering to the thymus an effective amount of (1) bone morphogenetic protein 4 (BMP4), (2) thymus-derived endothelial cells that express BMP4 or (3) a combination of BMP4 and BMP4-secreting thymus-derived endothelial cells.

Claims (12)

1. A method to promote thymic regeneration and/or enhance thymic epithelial cell function following injury or damage to the thymus, the method comprising exposing the thymus to an effective amount of thymus-derived endothelial cells that secrete BMP4.

2. The method of claim 1 , wherein the injury or damage to the thymus is due to aging, stress, infection, cytoreductive chemotherapy, corticosteroids, or radiation.

3. The method of claim 1 , wherein the thymic endothelial cells are transduced with a viral gene.

4. The method of claim 3 , wherein the viral gene is an adenoviral gene.

5. The method of claim 4 , wherein the adenoviral gene is E4ORF1.

6. The method of claim 1 , wherein the endothelial cells are CD45 − VE-Cadherein + .

7. The method of claim 1 , wherein BMP4 secreting thymic endothelial cells are administered to the thymus 1 day before the onset of injury or damage.

8. The method of claim 1 , wherein BMP4 secreting thymic endothelial cells are administered to the thymus from 1 to 5 days following damage or injury.

9. The method of claim 1 , wherein BMP4 secreting thymic endothelial cells are administered intravenously.

10. The method of claim 1 , wherein BMP4 secreting thymic endothelial cells are administered intrathymically.

11. The method of claim 1 , wherein the promotion of thymic regeneration is characterized by an increased number of mature functional T-cells in the thymus.

12. The method of claim 1 , wherein the enhanced thymic epithelial cell function is characterized by an increased number of mature functional T-cells in the thymus.

Assignments (2)
CONFIRMATORY LICENSE Recorded Aug 16, 2017
From: SLOAN-KETTERING INST CAN RESEARCH
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 043571/0116 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 11, 2017
From: DUDAKOV, JARROD; VAN DEN BRINK, MARCEL; WERTHEIMER, TOBIAS
To: MEMORIAL SLOAN-KETTERING CANCER CENTER
Reel/Frame 042336/0013 →
Continuity (4)
Continuation PCTUS2015058095 · Oct 29, 2015
Provisional Application 62086928 · Dec 3, 2014
Provisional Application 62069896 · Oct 29, 2014
Related Publication 20170292111A1 · Oct 12, 2017
Cited By (1)
US 12,569,494